CRA is a proud sponsor of Europe’s largest congress in market access, pricing and evidence featuring 250 speakers, 10 tracks and 1500+ attendees from pharma, biotech and Payers/HTA’s.
Andras Ruppert presents the session titled “Factors Impacting GKV Rebates for Orphan Drugs (OD) and the Evolution of OD Pricing in Germany.”
Abstract: While manufacturers set list prices for drugs in Germany at launch, subsequent GBA assessments and GKV rebate negotiations have a significant impact on their net prices. This is also true for Orphan Drugs (OD), despite existing protective measures. Leveraging CRA’s proprietary RADAR database, the research presents key factors that impact GKV rebates for ODs, and explores the evolution of OD list prices and rebates between 2013 and 2024.
For more information on this event, click here.
